Last updated: August 1, 2026
Benazepril hydrochloride/hydrochlorothiazide is an established fixed-dose combination of an angiotensin-converting enzyme inhibitor and a thiazide diuretic for hypertension. Its clinical development is complete, its brand-era patent protection has expired, and the current market is generic. No meaningful late-stage innovation pipeline or biosimilar issue exists. Commercial prospects depend on low-cost manufacturing, pharmacy distribution, formulary access and continued use of combination therapy rather than on new clinical differentiation.
What is benazepril hydrochloride and hydrochlorothiazide used for?
Benazepril hydrochloride/hydrochlorothiazide is indicated for the treatment of hypertension in patients who require combination therapy. Benazepril inhibits conversion of angiotensin I to angiotensin II, while hydrochlorothiazide promotes renal sodium and water excretion. The combination lowers blood pressure through complementary mechanisms.
The U.S. product was marketed as Lotensin HCT by Novartis. Available strengths historically included:
| Strength |
Benazepril hydrochloride |
Hydrochlorothiazide |
| Low dose |
10 mg |
12.5 mg |
| Intermediate dose |
20 mg |
12.5 mg |
| Higher diuretic dose |
20 mg |
25 mg |
| Higher ACE-inhibitor dose |
40 mg |
25 mg |
The exact availability of strengths varies by manufacturer and market. Current generic labeling should be used for product-specific strengths, inactive ingredients and distribution status.
The combination is generally used when blood pressure is inadequately controlled with either component alone or when a clinician selects initial combination therapy for patients expected to need multiple antihypertensive agents. The FDA label identifies contraindications including pregnancy, prior angioedema associated with an renin-angiotensin system inhibitor and coadministration with aliskiren in patients with diabetes. [1]
What clinical trials support benazepril hydrochloride and hydrochlorothiazide?
The clinical evidence is mature rather than pipeline-driven. Historical studies evaluated blood-pressure reduction, dose response and tolerability for benazepril, hydrochlorothiazide and their combination. Contemporary registration work for this product class generally relied on established pharmacology and comparative antihypertensive efficacy rather than large cardiovascular-outcomes trials for the specific fixed-dose tablet.
Clinical development status
| Development category |
Status |
| Pivotal hypertension registration studies |
Completed |
| Fixed-dose combination efficacy studies |
Historical |
| Cardiovascular-outcomes trial for the specific combination |
No established dedicated outcomes program |
| Phase 2 or Phase 3 innovation program |
None of commercial significance identified |
| Pediatric development |
Not a major current development focus |
| Oncology, immunology or rare-disease trials |
Not applicable |
| Biosimilar development |
Not applicable |
ClinicalTrials.gov is not a reliable source of commercial activity for this product because the combination is an old generic antihypertensive rather than an active branded development program. Searches may identify historical or investigator-led studies involving ACE inhibitors, thiazides or hypertension, but those studies do not indicate a new sponsor-driven development cycle for benazepril/hydrochlorothiazide. [2]
What did historical studies show?
The clinical rationale is based on additive blood-pressure lowering. ACE inhibition reduces vasoconstriction and aldosterone-mediated sodium retention. Hydrochlorothiazide reduces extracellular fluid volume and vascular resistance. Combining the agents can improve blood-pressure control while allowing lower doses of each component.
The principal safety issues are also mechanistically predictable:
- Hyperkalemia, particularly in patients with renal impairment or diabetes.
- Hypokalemia and hyponatremia from hydrochlorothiazide.
- Hypotension and volume depletion.
- Increased serum creatinine or acute kidney injury.
- Cough and angioedema from benazepril.
- Photosensitivity, hyperuricemia and glucose or lipid changes associated with hydrochlorothiazide.
- Fetal toxicity from ACE inhibition during pregnancy.
The FDA label recommends monitoring renal function and serum potassium, with greater attention in patients using potassium supplements, potassium-sparing diuretics, nonsteroidal anti-inflammatory drugs or other renin-angiotensin system inhibitors. [1]
What is the FDA regulatory status of benazepril hydrochloride/hydrochlorothiazide?
Benazepril hydrochloride/hydrochlorothiazide is an FDA-approved prescription combination marketed through abbreviated new drug applications. The product is a conventional oral tablet, not a biologic, complex injectable or drug-device combination.
The regulatory profile has four commercial consequences:
- New entrants generally rely on ANDA approval rather than a full new drug application.
- Generic manufacturers must demonstrate pharmaceutical equivalence and bioequivalence to the reference product.
- Clinical efficacy studies are usually unnecessary for each generic applicant.
- FDA approval depends heavily on manufacturing controls, dissolution, analytical comparability and facility compliance.
The reference product was Lotensin HCT. FDA labeling remains the principal source for indication, contraindications, warnings, dosing and pharmacokinetic information. The Orange Book should be checked for the current reference-listed drug, therapeutic equivalence codes and any active patent or exclusivity entries. [3]
What patents protect benazepril hydrochloride and hydrochlorothiazide?
The original composition and product patents for the branded combination have expired. Benazepril and hydrochlorothiazide are both long-established small molecules, and the U.S. market has been open to generic competition for many years.
| IP category |
Current commercial position |
| Benazepril compound patent |
Expired |
| Hydrochlorothiazide compound patent |
Expired |
| Original fixed-dose combination patent estate |
Expired |
| Brand formulation exclusivity |
Expired |
| Pediatric exclusivity |
No current commercial relevance |
| Active biologic exclusivity |
Not applicable |
| Generic formulation patents |
Possible at applicant or supplier level, but unlikely to create meaningful market-wide exclusivity |
Patent protection can still exist around manufacturing processes, crystalline forms, excipients or packaging for an individual supplier. Those rights would generally be narrower than the expired product rights and would not prevent all competitors from marketing the combination.
When did benazepril hydrochloride/hydrochlorothiazide lose exclusivity?
The product lost meaningful brand exclusivity after expiration of the original patent and regulatory exclusivity period. The commercially relevant result is the presence of multiple generic suppliers and the absence of a protected branded franchise.
No current patent term extension or meaningful regulatory exclusivity is expected to delay ordinary generic competition for the legacy product.
What is the Orange Book status of Lotensin HCT?
Lotensin HCT is a legacy reference product. The Orange Book is relevant for confirming the listed reference product, dosage forms and any remaining patent certifications. For an old generic combination such as benazepril/hydrochlorothiazide, current competitive risk is generally driven by:
- Number of approved ANDAs.
- Whether approved products remain actively marketed.
- Drug-supply shortages or manufacturing discontinuations.
- Wholesaler and pharmacy purchasing decisions.
- State substitution rules and payer formularies.
A Paragraph IV dispute would be commercially unusual at this stage because the principal product patents have expired. Any new Paragraph IV filing would more likely involve a later-developed formulation or process patent than the core combination itself.
Which companies are challenging the benazepril/hydrochlorothiazide market?
The market is challenged by generic manufacturers rather than by a single high-profile litigation campaign. U.S. generic antihypertensive suppliers commonly compete through broad portfolios that include ACE inhibitors, thiazides and other combination products. The relevant competitive set can include products marketed by major generic companies and contract manufacturers, depending on current FDA approval and commercial supply.
A complete competitor list requires a current FDA product and marketing-status review because ANDA approvals, discontinuations and labeler ownership change over time. The commercial market is fragmented, with price competition more important than brand-level differentiation.
What patent litigation and settlement agreements affect the product?
No major active patent litigation is associated with the legacy benazepril/hydrochlorothiazide combination as a central commercial issue. The product’s old age and generic availability reduce the probability of a settlement-driven delayed-entry event.
A litigation review should distinguish among:
- Litigation involving benazepril alone.
- Litigation involving other ACE inhibitor combinations.
- Litigation involving hydrochlorothiazide as an ingredient in a different product.
- Contract-manufacturing or supply disputes.
- Product-liability actions involving renal injury, angioedema or pregnancy exposure.
Those categories do not necessarily affect generic entry for the fixed-dose combination.
How strong is the patent estate for benazepril hydrochloride/hydrochlorothiazide?
The patent estate is weak from an exclusivity perspective and moderate only as a defensive manufacturing asset.
| Patent-strength factor |
Assessment |
| Core active ingredients |
Very weak; long expired |
| Fixed-dose combination |
Weak; legacy protection expired |
| Formulation barriers |
Low for conventional tablets |
| Manufacturing complexity |
Low to moderate |
| Regulatory barriers |
Low for qualified ANDA applicants |
| Litigation leverage |
Low |
| Ability to support premium pricing |
Minimal |
| Biosimilar barrier |
Not applicable |
The principal remaining barriers are operational. They include validated manufacturing capacity, API sourcing, quality-system compliance, stability data, analytical methods and reliable supply to wholesalers.
What formulations are protected by benazepril/hydrochlorothiazide patents?
The commercial product is an immediate-release oral tablet. There is no widely recognized current market advantage from an extended-release, abuse-deterrent, long-acting injectable or transdermal formulation.
Potential formulation rights could cover:
- Specific benazepril-to-hydrochlorothiazide ratios.
- Tablet coatings.
- Excipients and stability systems.
- Dissolution profiles.
- Manufacturing methods.
- Packaging designed to control moisture or degradation.
These rights are unlikely to create meaningful market exclusivity unless they are tied to a clinically differentiated formulation with FDA-recognized regulatory protection. No such commercially important formulation franchise is established for this product.
How does benazepril/hydrochlorothiazide compare with competing antihypertensive combinations?
The product competes with several low-cost categories:
| Combination class |
Commercial comparison |
| ACE inhibitor/thiazide |
Similar mechanism; benazepril combination is a mature generic |
| ARB/thiazide |
Often preferred when ACE-inhibitor cough occurs |
| ACE inhibitor/calcium-channel blocker |
Useful when diuretic exposure is undesirable |
| ARB/calcium-channel blocker |
Strong generic and branded competition |
| Single-agent therapy |
Lower pill burden only when blood pressure is controlled |
| Separate-component therapy |
Offers flexible dose titration but may reduce adherence |
The main clinical disadvantage is the ACE-inhibitor class risk of cough and angioedema. ARB-based combinations can be favored in patients with prior ACE-inhibitor intolerance. The main advantage of the fixed-dose product is convenience and potentially improved adherence compared with two separate tablets.
What is the market size and revenue exposure?
Public financial reports generally do not disclose revenue for benazepril hydrochloride/hydrochlorothiazide as a standalone product. The combination is too mature and generic for most suppliers to report it separately.
Commercial value is concentrated in volume, not price. Revenue exposure is affected by:
- Low average selling prices.
- Generic substitution.
- Number of active suppliers.
- Contract and government reimbursement.
- Product discontinuations.
- API and packaging costs.
- Pharmacy benefit manager reimbursement.
- Hospital and institutional purchasing.
The product is unlikely to generate material branded revenue. It can contribute incremental portfolio revenue for manufacturers that already have hypertension products, but it is unlikely to justify a standalone commercial infrastructure or major clinical investment.
Market projection
The most defensible base-case projection is stable-to-declining nominal revenue over the medium term, with unit demand remaining relatively resilient. Hypertension prevalence supports continued use, but generic price erosion and substitution by other fixed-dose combinations limit growth.
| Projection factor |
Direction |
| Hypertension treatment demand |
Positive |
| Use of fixed-dose combinations |
Positive |
| Generic price |
Negative |
| Brand premium |
Negative |
| New clinical differentiation |
Neutral to negative |
| Supply-chain opportunities |
Selectively positive |
| Long-term revenue growth |
Low or negative |
A manufacturer could improve economics through dependable supply, low-cost API procurement, multi-strength availability and inclusion in broad generic portfolios. A new branded launch would face poor return prospects without a meaningful adherence, tolerability or delivery advantage.
What generic entry risks exist?
Generic entry risk is already realized rather than prospective. The market has generic competition, and any remaining commercial risk comes from additional suppliers, price reductions or customer switching.
Generic launch scenarios
Base case: Existing generic supply continues, with modest price erosion and stable prescription demand.
Downside case for manufacturers: Additional ANDA suppliers enter or major purchasers consolidate volume, causing rapid price compression.
Supply-constrained case: One or more suppliers discontinue production, creating temporary shortages and improving pricing for remaining manufacturers.
Product-improvement case: A company introduces a more convenient combination or packaging format, but regulatory and commercial differentiation would be limited.
No credible scenario supports restoration of durable exclusivity for the conventional tablet.
What manufacturing and intellectual-property barriers remain?
Manufacturing is technically manageable but requires control of two active ingredients with different stability and analytical requirements. Key execution points include:
- API identity, purity and impurity controls.
- Uniformity of benazepril and hydrochlorothiazide across the tablet.
- Moisture and degradation management.
- Dissolution performance for both components.
- Stability through the labeled shelf life.
- Consistent supply of multiple strengths.
- FDA inspection readiness.
- Compliance with current good manufacturing practice requirements.
These barriers can exclude weak suppliers, but they do not create a durable patent moat. A manufacturer with reliable capacity can compete; a manufacturer with recurring quality or supply failures can lose formulary and wholesaler access quickly.
What is the outlook for clinical development and licensing?
A new clinical development program for the conventional combination is unlikely. The product does not have a meaningful orphan, specialty, biologic or hospital innovation pathway.
Licensing activity is more likely to involve:
- Regional commercialization rights.
- Generic portfolio acquisitions.
- Contract manufacturing.
- API supply agreements.
- Product-transfer transactions.
- Bundled antihypertensive portfolios.
A standalone licensing deal based solely on benazepril/hydrochlorothiazide would likely have limited strategic value. The combination may be included in broader transactions involving cardiovascular generics.
Key Takeaways
- Benazepril hydrochloride/hydrochlorothiazide is an established generic antihypertensive combination.
- Clinical development is complete; no major active innovation program is associated with the product.
- The FDA-approved dosage form is an immediate-release oral tablet.
- Original compound, combination and brand-era exclusivity have expired.
- Paragraph IV litigation and settlement risk are low for the legacy product.
- Biosimilar competition is irrelevant because the product contains small-molecule drugs.
- Revenue is not normally disclosed separately and is likely modest on a per-product basis.
- Unit demand should remain relatively stable, while pricing faces continued generic pressure.
- The strongest commercial advantages are supply reliability, manufacturing cost and portfolio distribution.
- The product has limited value as a standalone licensing or clinical-development asset.
FAQs
Is benazepril/hydrochlorothiazide still being prescribed?
Yes. It remains a therapeutic option for hypertension, although prescribing varies by market, clinician preference, formulary policy and the availability of other ACE inhibitor, ARB and calcium-channel blocker combinations.
Is benazepril/hydrochlorothiazide interchangeable with lisinopril/hydrochlorothiazide?
No. Both are ACE inhibitor/thiazide combinations, but they contain different ACE inhibitors and are not automatically substitutable on a milligram-for-milligram basis. Substitution depends on the prescriber, pharmacist and applicable regulatory rules.
Does benazepril/hydrochlorothiazide have cardiovascular-outcomes evidence?
The components and ACE inhibitor/thiazide treatment strategy have extensive hypertension evidence. A dedicated outcomes program for this exact fixed-dose product is not the main basis of its current use.
Can a company obtain new exclusivity for a benazepril/hydrochlorothiazide tablet?
A genuinely new formulation, manufacturing process or delivery system could potentially receive patent protection. A conventional tablet containing the established ingredients would face a high obviousness and freedom-to-operate burden.
Is benazepril/hydrochlorothiazide affected by the FDA’s generic-drug shortage framework?
It can be affected by general FDA drug-supply and manufacturing conditions. Shortage risk depends on active suppliers, production interruptions, API availability and FDA-listed product status rather than on patent exclusivity.
References
- U.S. Food and Drug Administration. (2019). Lotensin HCT (benazepril hydrochloride and hydrochlorothiazide) prescribing information.
- U.S. National Library of Medicine. (n.d.). ClinicalTrials.gov: Benazepril and hydrochlorothiazide clinical study records.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.
- Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017 ACC/AHA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension, 71(6), e13-e115.
